Sinem Burcu Kocaer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sinem Burcu Kocaer has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Fatos Onen
Division of Rheumatology, Department of Internal Medicine, Dokuz Eylul University School of Medicine, Izmir, Türkiye
5 shared publications - Ismail Sari
Division of Rheumatology, Department of Internal Medicine, Dokuz Eylul University School of Medicine, Izmir, Türkiye
4 shared publications - Merih Birlik
Division of Rheumatology, Department of Internal Medicine, Dokuz Eylul University School of Medicine, Izmir, Turkey
4 shared publications - Servet Akar
Division of Rheumatology, Department of Internal Medicine, Izmir Katip Celebi University Faculty of Medicine, Izmir, Turkey
4 shared publications - Ayse Cefle
Division of Rheumatology, Department of Internal Medicine, Kocaeli University Faculty of Medicine, Kocaeli, Türkiye
3 shared publications - Gökçe Kenar
Division of Rheumatology, Dokuz Eylul University Faculty of Medicine , Izmir
3 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Caleo in Rheumatology Quarterly
Biologic Therapy at Conception in Inflammatory Rheumatic Diseases: Real-World Experience and Pregnancy Outcomes
Objective: To describe real-world biologic treatment patterns, maternal disease activity, and pregnancy outcomes in women with inflammatory rheumatic diseases, and to explore biologic treatment selection patterns according to preconception planning status.Methods: This retrospective observational single-center study included women with inflammatory rheumatic diseases who conceived while receiving biologic disease-modifying antirheumatic drugs (bDMARDs) between 2015 and 2021. Data on clinical characteristics, treatment patterns, preconception planning, disease activity, and maternal-neonatal outcomes were extracted from medical records and analyzed using descriptive statistics.Results: Fifteen pregnancies were included. The mean maternal age at conception was 33.1 ± 4.0 years, and the median duration of bDMARD exposure before conception was 37 months (interquartile range [IQR]: 13-64). Spondyloarthritis and psoriatic arthritis were the most common diagnoses (n = 6, 40% each). Most pregnancies were planned (n = 12, 80%), and 10 patients (66.7%) received preconception counseling. At conception, 13 patients (86.7%) were in remission or partial remission. Certolizumab pegol was continued throughout pregnancy in 10 patients (66.7%), whereas adalimumab was discontinued during the first trimester in all 4 patients. Biologic therapy was restarted during pregnancy in 3 patients. Maternal and neonatal outcomes were generally favorable, with 1 case of premature rupture of membranes and 1 preterm birth at 35 weeks. No major congenital anomalies were observed.Conclusion: Although certolizumab pegol was the most frequently used biologic agent, biologic therapy was commonly discontinued during pregnancy, with reinitiation required in some patients. These findings support structured preconception planning and individualized biologic treatment decisions to maintain maternal disease control during pregnancy.
- 10 November 2026
- Published by Caleo in Rheumatology Quarterly
Open AccessBiologic Therapy at Conception in Inflammatory Rheumatic Diseases: Real-World Experience and Pregnancy Outcomes
Objective: To describe real-world biologic treatment patterns, maternal disease activity, and pregnancy outcomes in women with inflammatory rheumatic diseases, and to explore biologic treatment selection patterns according to preconception planning status.Methods: This retrospective observational single-center study included women with inflammatory rheumatic diseases who conceived while receiving biologic disease-modifying antirheumatic drugs (bDMARDs) between 2015 and 2021. Data on clinical characteristics, treatment patterns, preconception planning, disease activity, and maternal-neonatal outcomes were extracted from medical records and analyzed using descriptive statistics.Results: Fifteen pregnancies were included. The mean maternal age at conception was 33.1 ± 4.0 years, and the median duration of bDMARD exposure before conception was 37 months (interquartile range [IQR]: 13-64). Spondyloarthritis and psoriatic arthritis were the most common diagnoses (n = 6, 40% each). Most pregnancies were planned (n = 12, 80%), and 10 patients (66.7%) received preconception counseling. At conception, 13 patients (86.7%) were in remission or partial remission. Certolizumab pegol was continued throughout pregnancy in 10 patients (66.7%), whereas adalimumab was discontinued during the first trimester in all 4 patients. Biologic therapy was restarted during pregnancy in 3 patients. Maternal and neonatal outcomes were generally favorable, with 1 case of premature rupture of membranes and 1 preterm birth at 35 weeks. No major congenital anomalies were observed.Conclusion: Although certolizumab pegol was the most frequently used biologic agent, biologic therapy was commonly discontinued during pregnancy, with reinitiation required in some patients. These findings support structured preconception planning and individualized biologic treatment decisions to maintain maternal disease control during pregnancy.
- 6 September 2026
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 127 (11) , 5181-5187
Vestibular Dysfunction and Disease Activity in Rheumatoid Arthritis: A Controlled cVEMP Study
- 6 September 2026
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 127 (11) , 5181-5187
Vestibular Dysfunction and Disease Activity in Rheumatoid Arthritis: A Controlled cVEMP Study
- Open Access
- 21 March 2025
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 8 (2) , 292-297
Does the presence of comorbidities in rheumatoid arthritis patients impact initial tumor necrosis factor inhibitor treatment response and retention rates?
Aims: We aimed to evaluate the effect of comorbidities on the first tumor necrosis factor inhibitor (TNFi) treatment response and retention in patients with rheumatoid arthritis (RA). Methods: The study included adult RA patients (with M05 and M06 ICD codes) registered in the TURKBIO database and receiving their first TNFi treatment. Data on demographic, clinical, and laboratory features, disease activity scores, and other follow-up parameters (at the beginning and months 6 and 12) were collected. The Log-Rank test and Kaplan-Meier curve were used to determine the TNFi retention rates. Results: There were 1172 bio-naive RA patients who initiated their first TNFi treatments. The median age (IQR) of the patients was 53 (51-61), and 79.8% (n=935) were women. The most commonly used TNFi was etanercept (38.9%), followed by adalimumab (27.9%), certolizumab (13.8%), golimumab (10.8%), and infliximab (8.7%). The most prevalent comorbidities in patients were hypertension (32.6%), obesity (32.6%), osteoporosis (22.3%), asthma/COPD (17.9%), and diabetes mellitus (15.7%). The presence of comorbidities at the beginning of TNFi treatment did not affect DAS28 CRP responses at months 6 and 12 (p=0.18 and p=0.83, respectively) and the continuation rates of the first TNFi drug. After conducting a thorough analysis that factored in variables including gender, age over 60 years, smoking, serologic status, presence of erosion, and basal disease activity scores, it was determined that there were no statistically significant hazard ratios (HR) for the first TNFi persistence. However, there was a 5% decrease in adherence to the first TNFi drug with an increase in median disease duration (HR 0.95, 95% CI=0.90-1.00, p=0.048). Conclusion: It has been observed that the presence of comorbidities in patients with RA does not significantly affect the TNFi treatment response and retention rate. However, evidence suggests that as the duration of the disease increases, the continuation of the first TNFi drug may decrease.
- 21 March 2025
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 8 (2) , 292-297
Open AccessDoes the presence of comorbidities in rheumatoid arthritis patients impact initial tumor necrosis factor inhibitor treatment response and retention rates?
Aims: We aimed to evaluate the effect of comorbidities on the first tumor necrosis factor inhibitor (TNFi) treatment response and retention in patients with rheumatoid arthritis (RA). Methods: The study included adult RA patients (with M05 and M06 ICD codes) registered in the TURKBIO database and receiving their first TNFi treatment. Data on demographic, clinical, and laboratory features, disease activity scores, and other follow-up parameters (at the beginning and months 6 and 12) were collected. The Log-Rank test and Kaplan-Meier curve were used to determine the TNFi retention rates. Results: There were 1172 bio-naive RA patients who initiated their first TNFi treatments. The median age (IQR) of the patients was 53 (51-61), and 79.8% (n=935) were women. The most commonly used TNFi was etanercept (38.9%), followed by adalimumab (27.9%), certolizumab (13.8%), golimumab (10.8%), and infliximab (8.7%). The most prevalent comorbidities in patients were hypertension (32.6%), obesity (32.6%), osteoporosis (22.3%), asthma/COPD (17.9%), and diabetes mellitus (15.7%). The presence of comorbidities at the beginning of TNFi treatment did not affect DAS28 CRP responses at months 6 and 12 (p=0.18 and p=0.83, respectively) and the continuation rates of the first TNFi drug. After conducting a thorough analysis that factored in variables including gender, age over 60 years, smoking, serologic status, presence of erosion, and basal disease activity scores, it was determined that there were no statistically significant hazard ratios (HR) for the first TNFi persistence. However, there was a 5% decrease in adherence to the first TNFi drug with an increase in median disease duration (HR 0.95, 95% CI=0.90-1.00, p=0.048). Conclusion: It has been observed that the presence of comorbidities in patients with RA does not significantly affect the TNFi treatment response and retention rate. However, evidence suggests that as the duration of the disease increases, the continuation of the first TNFi drug may decrease.
- Open Access
- 20 June 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-9
Assessing safety and efficacy of TNFi treatment in late onset ankylosing spondylitis: a TURKBIO registry study
Clinical data on the use of tumour necrosis factor inhibitors (TNFi) in late-onset ankylosing spondylitis (LoAS) are limited. The present study aimed to evaluate efficacy, safety, and treatment adherence associated with the initial use of TNFi therapy in biologic naive patients diagnosed with LoAS. Patients whose age of onset was ≥ 45 years and < 45 years were classified as having LoAS and YoAS, respectively, based on the age of symptom onset. There were 2573 patients with YoAS and 281 LoAS. Baseline disease activity measures were similar between the groups. No significant differences were seen between the two groups in response to treatment and in remaining on the first TNFi at 6, 12 and 24 months. In the LoAS group, the analysis showed that TNFi discontinuation was linked to VAS pain score (HR 1.04; 95% CI 1.01–1.06). Patient groups had similar rates of adverse events (YoAS: 8.7% vs. LoAS: 11.7%). In both biologic naive LoAS and YoAS patients, the study showed that the initial TNFi therapy was equally effective and safe.
- 20 June 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-9
Open AccessAssessing safety and efficacy of TNFi treatment in late onset ankylosing spondylitis: a TURKBIO registry study
Clinical data on the use of tumour necrosis factor inhibitors (TNFi) in late-onset ankylosing spondylitis (LoAS) are limited. The present study aimed to evaluate efficacy, safety, and treatment adherence associated with the initial use of TNFi therapy in biologic naive patients diagnosed with LoAS. Patients whose age of onset was ≥ 45 years and < 45 years were classified as having LoAS and YoAS, respectively, based on the age of symptom onset. There were 2573 patients with YoAS and 281 LoAS. Baseline disease activity measures were similar between the groups. No significant differences were seen between the two groups in response to treatment and in remaining on the first TNFi at 6, 12 and 24 months. In the LoAS group, the analysis showed that TNFi discontinuation was linked to VAS pain score (HR 1.04; 95% CI 1.01–1.06). Patient groups had similar rates of adverse events (YoAS: 8.7% vs. LoAS: 11.7%). In both biologic naive LoAS and YoAS patients, the study showed that the initial TNFi therapy was equally effective and safe.
- Open Access
- 17 December 2023
- Published by MediHealth Academy in Kastamonu Medical Journal
- Vol. 3 (4) , 216-217
Concurrent diagnosis of Sjogren’s syndrome and polycthemia vera: a rare co-existence
Primary Sjogren's Syndrome(pSS) is a chronic autoimmune disease and focal lymphocytic infiltration of the exocrine glands is the key pathological feature (1). Polycythemia vera(PV) is a chronic myeloproliferative disorder characterized by JAK-2 mutations and increased red blood cell mass(2,3). Autoimmune diseases and hematological malignancies can often be observed together. Patients with SS are at a higher risk of developing lymphoproliferative diseases mainly low-grade B-cell lymphomas and predominantly marginal zone lymphoma. Moreover, PV can rarely be presented with paraneoplastic events including small vessel vasculitis (2). However, PV and pSS co-existence had never been reported. We here want to present a case of concurrently diagnosed PV and pSS.
- 17 December 2023
- Published by MediHealth Academy in Kastamonu Medical Journal
- Vol. 3 (4) , 216-217
Open AccessConcurrent diagnosis of Sjogren’s syndrome and polycthemia vera: a rare co-existence
Primary Sjogren's Syndrome(pSS) is a chronic autoimmune disease and focal lymphocytic infiltration of the exocrine glands is the key pathological feature (1). Polycythemia vera(PV) is a chronic myeloproliferative disorder characterized by JAK-2 mutations and increased red blood cell mass(2,3). Autoimmune diseases and hematological malignancies can often be observed together. Patients with SS are at a higher risk of developing lymphoproliferative diseases mainly low-grade B-cell lymphomas and predominantly marginal zone lymphoma. Moreover, PV can rarely be presented with paraneoplastic events including small vessel vasculitis (2). However, PV and pSS co-existence had never been reported. We here want to present a case of concurrently diagnosed PV and pSS.
- Open Access
- 27 July 2023
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 17 (07) , 944-952
How has the COVID-19 pandemic affected our rheumatology patients using biological/targeted DMARDs?
Introduction: We aimed to investigate the effects of the coronavirus disease 2019 (COVID-19) pandemic on the course and treatment of patients with inflammatory rheumatic musculoskeletal disease (iRMD) using biologic or targeted synthetic disease modifying and rheumatic drugs (b/tsDMARDs). Methodology: The study was carried out in two stages: in the first stage we investigated the delay of b/tsDMARD treatment in the first 3 months of the pandemic; in the second stage, we investigated all patients who decided to continue treatment after interruption in the 12-month period. Results: A total of 521 patients were included in the study. The iRMD diagnosis was listed as spondyloarthritis (SpA) (54.3%), rheumatoid arthritis (RA) (25.7%), psoriatic arthritis (PsA) (8.4%), vasculitis (6.1%), and others (5.4%). Concurrent use of hydroxychloroquine (hazard ratio [HR] = 1.49), iv bDMARD use (HR = 1.34), and a history of discontinuation of drug in the first 3 months of the pandemic (HR = 1.19) were determined as factors that reduced 12-month drug retention rates. The use of glucocorticoid (HR = 3.81) and having a diagnosis of interstitial lung disease/chronic obstructive lung disease (HR = 4.96) were found to increase the risk of being infected by SARS coronavirus 2 (SARS-CoV-2). Conclusions: It was shown that approximately 1/5 of iRMD patients using b/tsDMARDs delayed their treatment due to the fear of COVID-19 in the first three months of the pandemic process. However, with good communication with the patients, b/tsDMARD treatment was restarted and the 12-month drug retention status was quite high.
- 27 July 2023
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 17 (07) , 944-952
Open AccessHow has the COVID-19 pandemic affected our rheumatology patients using biological/targeted DMARDs?
Introduction: We aimed to investigate the effects of the coronavirus disease 2019 (COVID-19) pandemic on the course and treatment of patients with inflammatory rheumatic musculoskeletal disease (iRMD) using biologic or targeted synthetic disease modifying and rheumatic drugs (b/tsDMARDs). Methodology: The study was carried out in two stages: in the first stage we investigated the delay of b/tsDMARD treatment in the first 3 months of the pandemic; in the second stage, we investigated all patients who decided to continue treatment after interruption in the 12-month period. Results: A total of 521 patients were included in the study. The iRMD diagnosis was listed as spondyloarthritis (SpA) (54.3%), rheumatoid arthritis (RA) (25.7%), psoriatic arthritis (PsA) (8.4%), vasculitis (6.1%), and others (5.4%). Concurrent use of hydroxychloroquine (hazard ratio [HR] = 1.49), iv bDMARD use (HR = 1.34), and a history of discontinuation of drug in the first 3 months of the pandemic (HR = 1.19) were determined as factors that reduced 12-month drug retention rates. The use of glucocorticoid (HR = 3.81) and having a diagnosis of interstitial lung disease/chronic obstructive lung disease (HR = 4.96) were found to increase the risk of being infected by SARS coronavirus 2 (SARS-CoV-2). Conclusions: It was shown that approximately 1/5 of iRMD patients using b/tsDMARDs delayed their treatment due to the fear of COVID-19 in the first three months of the pandemic process. However, with good communication with the patients, b/tsDMARD treatment was restarted and the 12-month drug retention status was quite high.
- 23 May 2022
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 25 (7) , 775-780
Metabolic syndrome is associated with increased cardiovascular risk and disease damage in patients with Takayasu arteritis
Objective: Metabolic syndrome (MetS) is one of the preventable risk factors for cardiovascular disease (CVD). The aim of this study was to investigate the effect of MetS on CVD and cumulative organ damage in a multi‐center, large cohort of patients with Takayasu arteritis (TAK).Methods: This is a cross‐sectional study involving 192 consecutive TAK patients from seven tertiary rheumatology centers in Turkey. Clinical data of TAK patients fulfilling the 1990 American College of Rheumatology classification criteria were collected from medical records. They were evaluated for risk factors of CVD, disease activity, damage, and MetS at their last visits.Results: A total of 192 consecutive TAK patients were included in this study. One hundred and fifty‐eight (82%) were female, the mean age was 43.3 ± 13 years, and mean disease duration was 13.5 ± 9.3 years. MetS was detected in 50 (26%) of the patients and CVD was detected in 28 (14.6%). The presence of MetS was detected as an independent risk factor for CVD (P < 0.001). In addition, the mean vasculitis damage index of the group with MetS was significantly higher than in the other patients (4.5 ± 3.3 vs 3.2 ± 2.2, respectively, P = 0.004).Conclusion: The presence of MetS in TAK is associated with increased CVD and disease damage. Awareness and management of MetS can improve disease prognosis in patients with TAK.
- 23 May 2022
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 25 (7) , 775-780
Metabolic syndrome is associated with increased cardiovascular risk and disease damage in patients with Takayasu arteritis
Objective: Metabolic syndrome (MetS) is one of the preventable risk factors for cardiovascular disease (CVD). The aim of this study was to investigate the effect of MetS on CVD and cumulative organ damage in a multi‐center, large cohort of patients with Takayasu arteritis (TAK).Methods: This is a cross‐sectional study involving 192 consecutive TAK patients from seven tertiary rheumatology centers in Turkey. Clinical data of TAK patients fulfilling the 1990 American College of Rheumatology classification criteria were collected from medical records. They were evaluated for risk factors of CVD, disease activity, damage, and MetS at their last visits.Results: A total of 192 consecutive TAK patients were included in this study. One hundred and fifty‐eight (82%) were female, the mean age was 43.3 ± 13 years, and mean disease duration was 13.5 ± 9.3 years. MetS was detected in 50 (26%) of the patients and CVD was detected in 28 (14.6%). The presence of MetS was detected as an independent risk factor for CVD (P < 0.001). In addition, the mean vasculitis damage index of the group with MetS was significantly higher than in the other patients (4.5 ± 3.3 vs 3.2 ± 2.2, respectively, P = 0.004).Conclusion: The presence of MetS in TAK is associated with increased CVD and disease damage. Awareness and management of MetS can improve disease prognosis in patients with TAK.
- 14 March 2022
- Published by Galenos Yayinevi in Namık Kemal Tıp Dergisi
- Vol. 10 (1) , 43-47
Training Course Results of the Assessment of Modified Rodnan Skin Score in Scleroderma
- 14 March 2022
- Published by Galenos Yayinevi in Namık Kemal Tıp Dergisi
- Vol. 10 (1) , 43-47
Training Course Results of the Assessment of Modified Rodnan Skin Score in Scleroderma
- 17 November 2021
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 25 (2) , 140-146
Pregnancy in Takayasu’s arteritis has a high risk of hypertension‐related fetomaternal complications: A retrospective study of a Turkish cohort
Background: This study aimed to examine fetomaternal outcomes in pregnant women in a large Turkish Takayasu arteritis (TAK) cohort and to evaluate the effects of pregnancy on the disease in those patients.Methods: This is a cohort study involving 296 pregnancies of 112 TAK patients from 8 tertiary rheumatology centers in Turkey. Pregnancies were divided into 2 groups as pre‐d (before disease onset) and post‐d (after disease onset). In addition, post‐d pregnancies were further divided into 2 subgroups according to fetomaternal complications (FMC) development status. Finally, patients were grouped into those with and without a history of pregnancy after disease onset.Results: In post‐d pregnancies, rates of worsening hypertension, new‐onset hypertension, and preeclampsia were higher than in pre‐d pregnancies (0.9% vs 16%, P < .001, 0.5% vs 5.3%, P = .012, and 0% vs 4%, P = .013, respectively). Patients with FMC were more likely to have renal artery involvement (65% vs 21%, P = .003). The patients who had post‐d were younger, had longer disease duration, and had more relapses number than other patients (P < .001, P = .028, P = .016, respectively). Vasculitis Damage Index (VDI) results were similar in patients with or without post‐d pregnancies.Conclusion: Pregnancies after disease onset were found to be associated with HT and preeclampsia/eclampsia. HT‐related FMCs are increased in TAK, and patients with renal artery involvement are at higher risk. The number of relapses increases in patients who become pregnant after disease onset, but pregnancy was not an independent risk factor for relapse. Pregnancy after the onset of disease had no negative effect on VDI.
- 17 November 2021
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 25 (2) , 140-146
Pregnancy in Takayasu’s arteritis has a high risk of hypertension‐related fetomaternal complications: A retrospective study of a Turkish cohort
Background: This study aimed to examine fetomaternal outcomes in pregnant women in a large Turkish Takayasu arteritis (TAK) cohort and to evaluate the effects of pregnancy on the disease in those patients.Methods: This is a cohort study involving 296 pregnancies of 112 TAK patients from 8 tertiary rheumatology centers in Turkey. Pregnancies were divided into 2 groups as pre‐d (before disease onset) and post‐d (after disease onset). In addition, post‐d pregnancies were further divided into 2 subgroups according to fetomaternal complications (FMC) development status. Finally, patients were grouped into those with and without a history of pregnancy after disease onset.Results: In post‐d pregnancies, rates of worsening hypertension, new‐onset hypertension, and preeclampsia were higher than in pre‐d pregnancies (0.9% vs 16%, P < .001, 0.5% vs 5.3%, P = .012, and 0% vs 4%, P = .013, respectively). Patients with FMC were more likely to have renal artery involvement (65% vs 21%, P = .003). The patients who had post‐d were younger, had longer disease duration, and had more relapses number than other patients (P < .001, P = .028, P = .016, respectively). Vasculitis Damage Index (VDI) results were similar in patients with or without post‐d pregnancies.Conclusion: Pregnancies after disease onset were found to be associated with HT and preeclampsia/eclampsia. HT‐related FMCs are increased in TAK, and patients with renal artery involvement are at higher risk. The number of relapses increases in patients who become pregnant after disease onset, but pregnancy was not an independent risk factor for relapse. Pregnancy after the onset of disease had no negative effect on VDI.
- Open Access
- 3 September 2021
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 32 (5) , 994-998
Rheumatologic manifestations in a cohort of patients with Vogt–Koyanagi–Harada disease
Objectives: Vogt–Koyanagi–Harada Disease (VKHD) is a systemic autoimmune disorder characterized by granulomatous panuveitis. Inflammatory rheumatic diseases (IRDs) are among the differential diagnosis of VKHD. However, current knowledge on the rheumatological aspects of VKHD is still limited. We aimed to investigate the prevalence of rheumatic conditions in VKHD patients. Methods: VKHD patients were included in the study and they were reviewed in terms of the presence of any rheumatological manifestations. Results: There were 18 patients with a female preponderance (83.3%, female). Inflammatory type of peripheral joint pain (11%) and sicca symptoms (33%) were the most common rheumatological findings. The frequency of spondyloarthritis-related features such as inflammatory back pain and HLA-B27 rate was not increased. None of the patients had radiographic sacroiliitis. Anti-nuclear antibody was positive in high titres nearly in 30% of the patients and three patients had antibodies against extractable nuclear antigens. Nailfold capillaroscopy was abnormal in about one-third of the patients. Pathergy test was negative in all cohorts. While angiotensin-converting enzyme was elevated in nearly 20% of the patients, there were no abnormalities on chest X-rays. Conclusion: VKHD shares some features with IRDs. The common features were mostly suggestive of connective tissue disease rather than SpA or rheumatoid arthritis.
- 3 September 2021
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 32 (5) , 994-998
Open AccessRheumatologic manifestations in a cohort of patients with Vogt–Koyanagi–Harada disease
Objectives: Vogt–Koyanagi–Harada Disease (VKHD) is a systemic autoimmune disorder characterized by granulomatous panuveitis. Inflammatory rheumatic diseases (IRDs) are among the differential diagnosis of VKHD. However, current knowledge on the rheumatological aspects of VKHD is still limited. We aimed to investigate the prevalence of rheumatic conditions in VKHD patients. Methods: VKHD patients were included in the study and they were reviewed in terms of the presence of any rheumatological manifestations. Results: There were 18 patients with a female preponderance (83.3%, female). Inflammatory type of peripheral joint pain (11%) and sicca symptoms (33%) were the most common rheumatological findings. The frequency of spondyloarthritis-related features such as inflammatory back pain and HLA-B27 rate was not increased. None of the patients had radiographic sacroiliitis. Anti-nuclear antibody was positive in high titres nearly in 30% of the patients and three patients had antibodies against extractable nuclear antigens. Nailfold capillaroscopy was abnormal in about one-third of the patients. Pathergy test was negative in all cohorts. While angiotensin-converting enzyme was elevated in nearly 20% of the patients, there were no abnormalities on chest X-rays. Conclusion: VKHD shares some features with IRDs. The common features were mostly suggestive of connective tissue disease rather than SpA or rheumatoid arthritis.